Breaking News

Leap, BeiGene Ink Exclusive Antibody Alliance

To develop and commercialize Leap’s DKN-01 anti-Dickkopf-1 antibody in gastric cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Leap Therapeutics, a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, biopharma company focused on molecularly-targeted and immuno-oncology drugs, entered an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap’s anti-Dickkopf-1 antibody, in Asia (excluding Japan), Australia, and New Zealand. Leap will retain exclusive rights for the development, manufacturing, and commercialization of DKN-01 for the r...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters